226
Sharifi S, Behzadi S, Laurent S, Forrest ML, Stroeve P, Mahmoudi M (2012) Toxicity of nanomaterials. Chem Soc Rev 41:2323–2343
Shatkin JA, Ong KJ (2016) Alternative testing strategies for Nanomaterials: State of the science
and considerations for risk analysis. Risk Anal 36:1564–1580
Shegokar R, Fernandes AR, Souto EB (2018) Chapter 1 – Nanopharmaceuticals in immunology:
what’s new in research? In: Shegokar R, Souto EB (eds) Emerging nanotechnologies in immunology. Elsevier, Boston, pp 1–22
Shin SW, Song IH, Um SH (2015) Role of physicochemical properties in nanoparticle toxicity.
Nanomaterials (Basel) 5:1351–1365
Silva AM, Alvarado HL, Abrego G, Martins-Gomes C, Garduno-Ramirez ML, Garcia ML,
Calpena AC, Souto EB (2019a) In vitro cytotoxicity of oleanolic/ursolic acids-loaded in PLGA
nanoparticles in different cell lines. Pharmaceutics 11:362
Silva AM, Martins-Gomes C, Fangueiro JF, Andreani T, Souto EB (2019b) Comparison of antiproliferative effect of epigallocatechin gallate when loaded into cationic solid lipid nanoparticles
against different cell lines. Pharm Dev Technol 24:1243–1249
Silva AM, Martins-Gomes C, Coutinho TE, Fangueiro JF, Sanchez-Lopez E, Pashirova TN,
Andreani T, Souto EB (2019c) Soft cationic nanoparticles for drug delivery: production and
cytotoxicity of Solid Lipid Nanoparticles (SLNs). Appl Sci 9:4438
Soliman GM (2017) Nanoparticles as safe and effective delivery systems of antifungal agents:
achievements and challenges. Int J Pharm 523:15–32
Sousa C, Pereira I, Santos AC, Carbone C, Kovacevic AB, Silva AM, Souto EB (2017) Targeting
dendritic cells for the treatment of autoimmune disorders. Colloids Surf B: Biointerfaces
158:237–248
Souto EB, Almeida AJ, Müller RH (2007) Lipid nanoparticles (SLN
® , NLC
®
) for cutaneous drug
delivery: structure, protection and skin effects. J Biomed Nanotechnol 3:317–331
Souto EB, Baldim I, Oliveira WP, Rao R, Yadav N, Gama FM, Mahant S (2020a) SLN and NLC
for topical, dermal and transdermal drug delivery. Expert Opin Drug Deliv 17:357–377
Souto EB, Zielinska A, Souto SB, Durazzo A, Lucarini M, Santini A, Silva AM, Atanasov AG,
Marques C, Andrade LN, Severino P (2020b) (+)-Limonene 1,2-epoxide-loaded SLN: evaluation of drug release, antioxidant activity and cytotoxicity in HaCaT cell line. Int J Mol Sci
21:E1449
Souto EB, Souto SB, Zielinska A, Durazzo A, Lucarini M, Santini A, Horbańczuk OK, Atanasov
AG, Marques C, Andrade LN, Silva AM, Severino P (2020c) Perillaldehyde 1,2-epoxide
loaded SLN-tailored mAb: production, physicochemical characterization and in vitro cytotoxicity profile in MCF-7 cell lines. Pharmaceutics 12:161
Souto EB, Campos JR, Da Ana R, Martins-Gomes C, Silva AM, Souto SB, Lucarini M, Durazzo
A, Santini A (2020d) Ocular cell lines and genotoxicity assessment. Int J Environ Res Public
Health 17
Stone V, Johnston H, Schins RP (2009) Development of in vitro systems for nanotoxicology: methodological considerations. Crit Rev Toxicol 39:613–626
Sturla SJ, Boobis AR, FitzGerald RE, Hoeng J, Kavlock RJ, Schirmer K, Whelan M, Wilks MF,
Peitsch MC (2014) Systems toxicology: from basic research to risk assessment. Chem Res
Toxicol 27:314–329
Surassmo S, Saengkrit N, Ruktanonchai UR, Suktham K, Woramongkolchai N, Wutikhun T,
Puttipipatkhachorn S (2015) Surface modification of PLGA nanoparticles by carbopol to
enhance mucoadhesion and cell internalization. Colloids Surf B: Biointerfaces 130:229–236
Suzuki YJ, Carini M, Butterfield DA (2010) Protein carbonylation. Antioxid Redox Signal
12:323–325
Szabo P, Zelko R (2015) Formulation and stability aspects of nanosized solid drug delivery systems. Curr Pharm Des 21:3148–3157
Teeguarden JG, Hinderliter PM, Orr G, Thrall BD, Pounds JG (2007) Particokinetics in vitro:
dosimetry considerations for in vitro nanoparticle toxicity assessments. Toxicol Sci 95:300–312
M. C. Teixeira et al.
Sharifi S, Behzadi S, Laurent S, Forrest ML, Stroeve P, Mahmoudi M (2012) Toxicity of nanomaterials. Chem Soc Rev 41:2323–2343
Shatkin JA, Ong KJ (2016) Alternative testing strategies for Nanomaterials: State of the science
and considerations for risk analysis. Risk Anal 36:1564–1580
Shegokar R, Fernandes AR, Souto EB (2018) Chapter 1 – Nanopharmaceuticals in immunology:
what’s new in research? In: Shegokar R, Souto EB (eds) Emerging nanotechnologies in immunology. Elsevier, Boston, pp 1–22
Shin SW, Song IH, Um SH (2015) Role of physicochemical properties in nanoparticle toxicity.
Nanomaterials (Basel) 5:1351–1365
Silva AM, Alvarado HL, Abrego G, Martins-Gomes C, Garduno-Ramirez ML, Garcia ML,
Calpena AC, Souto EB (2019a) In vitro cytotoxicity of oleanolic/ursolic acids-loaded in PLGA
nanoparticles in different cell lines. Pharmaceutics 11:362
Silva AM, Martins-Gomes C, Fangueiro JF, Andreani T, Souto EB (2019b) Comparison of antiproliferative effect of epigallocatechin gallate when loaded into cationic solid lipid nanoparticles
against different cell lines. Pharm Dev Technol 24:1243–1249
Silva AM, Martins-Gomes C, Coutinho TE, Fangueiro JF, Sanchez-Lopez E, Pashirova TN,
Andreani T, Souto EB (2019c) Soft cationic nanoparticles for drug delivery: production and
cytotoxicity of Solid Lipid Nanoparticles (SLNs). Appl Sci 9:4438
Soliman GM (2017) Nanoparticles as safe and effective delivery systems of antifungal agents:
achievements and challenges. Int J Pharm 523:15–32
Sousa C, Pereira I, Santos AC, Carbone C, Kovacevic AB, Silva AM, Souto EB (2017) Targeting
dendritic cells for the treatment of autoimmune disorders. Colloids Surf B: Biointerfaces
158:237–248
Souto EB, Almeida AJ, Müller RH (2007) Lipid nanoparticles (SLN
® , NLC
®
) for cutaneous drug
delivery: structure, protection and skin effects. J Biomed Nanotechnol 3:317–331
Souto EB, Baldim I, Oliveira WP, Rao R, Yadav N, Gama FM, Mahant S (2020a) SLN and NLC
for topical, dermal and transdermal drug delivery. Expert Opin Drug Deliv 17:357–377
Souto EB, Zielinska A, Souto SB, Durazzo A, Lucarini M, Santini A, Silva AM, Atanasov AG,
Marques C, Andrade LN, Severino P (2020b) (+)-Limonene 1,2-epoxide-loaded SLN: evaluation of drug release, antioxidant activity and cytotoxicity in HaCaT cell line. Int J Mol Sci
21:E1449
Souto EB, Souto SB, Zielinska A, Durazzo A, Lucarini M, Santini A, Horbańczuk OK, Atanasov
AG, Marques C, Andrade LN, Silva AM, Severino P (2020c) Perillaldehyde 1,2-epoxide
loaded SLN-tailored mAb: production, physicochemical characterization and in vitro cytotoxicity profile in MCF-7 cell lines. Pharmaceutics 12:161
Souto EB, Campos JR, Da Ana R, Martins-Gomes C, Silva AM, Souto SB, Lucarini M, Durazzo
A, Santini A (2020d) Ocular cell lines and genotoxicity assessment. Int J Environ Res Public
Health 17
Stone V, Johnston H, Schins RP (2009) Development of in vitro systems for nanotoxicology: methodological considerations. Crit Rev Toxicol 39:613–626
Sturla SJ, Boobis AR, FitzGerald RE, Hoeng J, Kavlock RJ, Schirmer K, Whelan M, Wilks MF,
Peitsch MC (2014) Systems toxicology: from basic research to risk assessment. Chem Res
Toxicol 27:314–329
Surassmo S, Saengkrit N, Ruktanonchai UR, Suktham K, Woramongkolchai N, Wutikhun T,
Puttipipatkhachorn S (2015) Surface modification of PLGA nanoparticles by carbopol to
enhance mucoadhesion and cell internalization. Colloids Surf B: Biointerfaces 130:229–236
Suzuki YJ, Carini M, Butterfield DA (2010) Protein carbonylation. Antioxid Redox Signal
12:323–325
Szabo P, Zelko R (2015) Formulation and stability aspects of nanosized solid drug delivery systems. Curr Pharm Des 21:3148–3157
Teeguarden JG, Hinderliter PM, Orr G, Thrall BD, Pounds JG (2007) Particokinetics in vitro:
dosimetry considerations for in vitro nanoparticle toxicity assessments. Toxicol Sci 95:300–312
M. C. Teixeira et al.